Singapore markets closed
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,463.29 -6.01 (-0.11%) Dow
38,973.64 -138.52 (-0.35%) Nasdaq
17,747.38 +29.72 (+0.17%) Bitcoin USD
61,742.13 +543.73 (+0.89%) CMC Crypto 200
1,278.94 -4.84 (-0.38%)
ITCI Jun 2024 70.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:33AM EDT. Market open.
| Previous close | 0.0500 |
| Open | 0.4600 |
| Bid | 0.0000 |
| Ask | 0.5000 |
| Strike | 70.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.4600 - 0.4600 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.07k |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.